Patrick Hsu in the lab

Research Bio

Patrick Hsu is Co-Founder and a Core Investigator of the Arc Institute and Assistant Professor of Bioengineering and Deb Faculty Fellow at the University of California, Berkeley. A pioneer in the fields of generative biology and CRISPR gene editing, Patrick’s work aims to accelerate scientific progress through innovation in biotechnology development, science funding, and research organizations. His research group works at the intersection of biology and machine learning, contributing the Evo series of biological foundation models, the first programmable recombinases, and the early development of CRISPR-Cas9 for human genome editing. He received A.M. and Ph.D. degrees from Harvard University and his research has been recognized by the New York Times Good Tech Award, one of The Most Important Breakthroughs of 2024 by The Atlantic and 5 Important Medical Breakthroughs Of 2024 by Forbes, Vox's Future Perfect 50, the MIT Technology Review’s Innovators Under 35, the Rainwater Prize for Innovative Early Career Scientists, the Amgen Young Investigator Award, and the NIH Early Independence Award. Outside of fundamental research, Patrick has co-founded multiple biotech companies, invests in AI startups, and helped to launch Fast Grants for rapid science funding.

Current Hsu Lab areas of interest:

Molecular Technologies: We invent molecular tools for biological programming by leveraging computational genome mining, functional biochemical and molecular assays, and protein engineering. Recent work from the lab include the first programmable DNA recombinases (bridge RNAs), the most widely used CRISPR tools for transcriptome engineering (Cas13d), and targeted genomic integration of large payloads (DNA integrases).

Merging Biology and AI: We work at the intersection of biology and AI by developing biological foundation models for generative DNA and protein design, as well as virtual cell models that can predict cellular response to chemical and genetic perturbations. We are also building AI agents for science to automate the process of making scientific breakthroughs.

Human Synthetic Biology: We aim to push the boundaries of synthetic biology in human cells via genome, epigenome, transcriptome, and protein engineering. First, we think backwards from major unmet therapeutic needs and then develop platform solutions that enable new kinds of genetic manipulations. Current areas of interest include cell type-specific control of biological perturbations, turning the dial on epigenetic memory, and manipulation of RNA splicing.

Research Expertise and Interest

generative biology, language models, virtual cell models, genome mining and editing, synthetic biology, AI agents for science

In the News

UC Berkeley Partners With New Arc Institute to Tackle Complex Diseases

UC Berkeley is partnering with UC San Francisco and Stanford University as founding scientific members of a new institute that aims to accelerate breakthroughs in complex diseases. The Arc Institute launched Dec. 15, 2021, with the goal of developing a new model for collaborative research that brings together world-class research with unconstrained funding to enable new discoveries that improve human health.

Using two CRISPR enzymes, a COVID diagnostic in only 20 minutes

Frequent, rapid testing for COVID-19 is critical to controlling the spread of outbreaks, especially as new, more transmissible variants emerge. A research team at the UC, Berkeley is aiming to develop a diagnostic test that is much faster and easier to deploy than the gold standard qRT-PCR diagnostic test. The team has now combined two different types of CRISPR enzymes to create an assay that can detect small amounts of viral RNA in less than an hour.

What COVID-19 antibody tests can tell us, and what they can’t

As the United States and much of the world move toward relaxing shelter-in-place restrictions to let people move about more freely, public health experts hope to rely on antibody tests to determine who has been infected with the COVID-19 virus and may be immune — at least temporarily — and who is still susceptible.

Featured in the Media

Please note: The views and opinions expressed in these articles are those of the authors and do not necessarily reflect the official policy or positions of UC Berkeley.
February 19, 2025

Biggest-ever AI biology model writes DNA on demand

Nature
Ewen Callaway

“We’re really looking forward to how scientists and engineers build this ‘app store’ for biology,” said Patrick Hsu, an assistant professor of bioengineering.

FullStory

June 29, 2020

Flawed COVID-19 Antibody Tests Shipped Without FDA Review

CBS News, 60 Minutes
Sharyn Alfonsi
A 60 Minutes investigation revealed that federal officials knew many of the antibody tests suddenly flooding the market were seriously flawed, but continued to allow them to be sold anyway. In early March, Dr. Alex Marson of UC San Francisco, and Dr. Patrick Hsu, an assistant professor of bioengineering at UC Berkeley, assembled a team of 50 scientists to do what the FDA had not: test the antibody tests. All but one test delivered so-called false-positives, meaning they mistakenly signaled antibodies in people who did not have them.
FullStory

June 16, 2020

Antibody Tests Are Everywhere Now and Confusing Everyone

Bloomberg Businessweek
Kristen V Brown
Coronavirus antibody testing is suddenly everywhere, but results are often incorrect or inconclusive. Patrick Hsu, an assistant professor of bioengineering at the University of California, Berkeley, was a senior author on a recent study on the accuracy of antibody tests. His group analyzed 14 tests and found only three produced consistently reliable results. "People want answers: Am I immune? Can I go back to work? Can I play soccer in the park?" Hsu says. "But the story's not quite so simple." He says that even for tests that can accurately detect the virus, many questions remain. For more on this, see our press release at Berkeley News
FullStory

May 13, 2020

Coronavirus Update: Hundreds of COVID-19 Antibody Tests with Questionable Accuracy Flood Market

KPIX TV
Maria Medina
It's been pretty well publicized that an intensive study of proliferating COVID-19 antibody tests, co-led by assistant bioengineering professor Patrick Hsu of the Berkeley-UCSF Innovative Genomics Institute, has found that very few are effective and all have flaws, but that has not discouraged many eager buyers. "There are over 200 different antibody tests out there right at this point, more than we have for any other infectious disease," Professor Hsu says. "One of the things that we're able to do in our study is to test on individual blood samples both positive and negative, all of these tests against each other, head to head, right, in this bake-off, systematically." The tests returned too many false positives, and only one, called Sure Biotech, was found to be 100% accurate. "Some were over 10 percent, and some were even over 15 percent false positive, right? So that would really not be acceptable performance," he says. Link to video. For more on this study, see our press release at Berkeley News.
FullStory

April 28, 2020

UC Berkeley, UCSF Announce Joint Study of COVID-19 Antibody Test Kits

NBC Bay Area Online
Bay City News
Assistant bioengineering professor Patrick Hsu, an investigator at Berkeley's Innovative Genomics Institute (IGI) is co-leading a massive UC Berkeley-UCSF joint effort to study more than 120 antibody test kits for their effectiveness in identifying people who may be immune to COVID-19. "These tests are widely available, and many people are buying and deploying them, but I realized that they had not been systematically validated, and we needed to figure out which ones would really work," Professor Hsu says. "This is a huge, unmet need for public health." Praising the project's enormous team of researchers, he says: "This is a huge, huge community effort. ... A lot of people really came together. One of the things I think is cool about this study is how many people repurposed themselves from what we normally do to respond to this pandemic." For more on this, see our press release at Berkeley News. Stories on this topic have appeared in dozens of sources, including Yahoo! News and Science Blog.
FullStory

April 27, 2020

Coronavirus Antibody Tests: Can You Trust the Results?

New York Times
Apoorva Mandavilli

For the past few weeks, more than 50 scientists have been working diligently to do something that the Food and Drug Administration mostly has not: Verifying that 14 coronavirus antibody tests now on the market actually deliver accurate results, this reporter writes, speaking of tests co-led by assistant bioengineering professor Patrick Hsu, an investigator at the Innovative Genomics Institute (IGI), a joint research collaboration between Berkeley and UCSF that is focused on CRISPR gene-editing technology. The team has found that only 3 of the 14 leading blood antibody tests they tested provided consistently reliable results, and even those three were flawed. The results are especially troublesome for their rate of false-positive results. I realized, 'Gosh this is really the Wild West,'" Professor Hsu says. "We needed to figure out which of these would really work." The accuracy of antibody tests is particularly important as states consider how they'll reopen safely, because they are critical for determining who is immune and would be safe to return to work. For more on this, see our press release at Berkeley News. Stories on this topic have appeared in dozens of sources, including U.S. News & World Report and KPIX TV--link to video.

FullStory (*requires registration)


Loading Class list ...